Chronic active Epstein-Barr virus disease

From IDWiki
Revision as of 01:34, 16 October 2020 by Aidan (talk | contribs)

Background

  • Life-threatening inflammatory disorder and lymphoid neoplasm caused by infection with Epstein-Barr virus involving NK and T cells

Pathophysiology

  • EBV infection involving B, T, and/or NK cells

Epidemiology

  • Most cases reported in Japan and East Asia
  • In the Americas, more common in Indigenous populations
  • However, can occur in people of all ethnicities

Clinical Manifestations

Related Disorders

Severe mosquito bite allergy

  • A severe hypersensitivity reaction to saliva in the bite of Aedes albopictus mosquitoes
  • Characterized by local skin inflammation followed by high fever, lymphadenopathy, and liver dysfunction
  • The bite can ulcerate and scar
  • Resoves within a month

Hydroa vacciniforme

  • Characterized by light-induced vesicles
  • Can also involve systemic inflammation

Diagnostic Criteria

  • Sustained or recurrent IM‐like symptoms for greater than 3 months
    • Symptoms include fever, lymphadenopathy, and hepatosplenomegaly, and possibly other symptoms
  • Elevated EBV genome load in the peripheral blood (>102.5 copies/µg DNA)
  • EBV infection of T or NK cells in the affected tissues or peripheral blood
  • Exclusion of other possible diagnoses including the following:
    • Primary EBV infection (infectious mononucleosis)
    • Primary immunodeficiencies
    • HIV
    • Iatrogenic immunosuppression
    • Autoimmune or collagen vascular diseases
    • Other malignant lymphoma (classic Hodgkin lymphoma, extranodal NK/T cell lymphoma, including nasal type, peripheral T cell lymphomas, and aggressive NK‐cell leukemia)

Diagnosis

  • Can follow a series of stepwise diagnostic tests:
    • Anti-EBV antibodies demonstrating anti-VCA-IgG (necessary for diagnosis), anti-EA-IgG, and anti-VCA-IgA or anti-EA-IgA antibodies
      • Anti-EBNA antibodies may be negative
    • EBV DNA viral load ≥102.5 copies/μg DNA
    • Detection of EBV infection of T or NK cells in affected tissues or peripheral blood

Management

Further Reading

  • Advances in the Study of Chronic Active Epstein-Barr Virus Infection: Clinical Features Under the 2016 WHO Classification and Mechanisms of Development. Front Pediatr. 2019;7:14. doi: 10.3389/fped.2019.00014

References

  1. ^  Hiroshi Kimura, Yo Hoshino, Hirokazu Kanegane, Ikuya Tsuge, Takayuki Okamura, Keisei Kawa, Tsuneo Morishima. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood. 2001;98(2):280-286. doi:10.1182/blood.v98.2.280.
  2. ^  Jeffrey I. Cohen, Elaine S. Jaffe, Janet K. Dale, Stefania Pittaluga, Helen E. Heslop, Cliona M. Rooney, Stephen Gottschalk, Catherine M. Bollard, V. Koneti Rao, Adriana Marques, Peter D. Burbelo, Siu-Ping Turk, Rachael Fulton, Alan S. Wayne, Richard F. Little, Mitchell S. Cairo, Nader K. El-Mallawany, Daniel Fowler, Claude Sportes, Michael R. Bishop, Wyndham Wilson, Stephen E. Straus. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood. 2011;117(22):5835-5849. doi:10.1182/blood-2010-11-316745.